Objective: The hypothesis was tested that the rate of postmenopausal bone loss is inversely associated with longterm urinary excretion of phyto-oestrogens, as a marker of habitual dietary intake. Design: Secondary analysis of a 10-year follow-up study (1979 ± 1989) among postmenopausal women in the Netherlands. Subjects: From the original population of 154 women, 32 women were selected with an annual rate of radial bone loss of 0.5% over the ®rst 5 years of the study and 35 women with a rate of ! 2.5% per year. Methods: The iso¯avonoids genistein, daidzein and equol, and the lignan enterolactone were determined by gas chromatography ± mass spectrometry in aggregate samples from annually collected urine samples. Cortical bone density of the radius had previously been measured annually by single-photon absorptiometry. Results: Excretion of iso¯avonoids did not differ between both groups, although in multivariate analysis equol excretion was weakly positively associated with rate of bone loss in the 5 years after the menopause. Enterolactone excretion was signi®cantly higher in the group with high rate of bone loss. This positive association remained in multivariate linear regression analysis after adjustment for age, years since menopause, body mass index and intake of calcium, vegetable protein and dietary ®bre. Conclusions: Enterolactone excretion is likely to be an indicator of consumption of grains and legumes; it is not clear whether the observed positive association with rate of bone loss is a causal one. Our results do not support a preventive effect of low, unsupplemented dietary intake of phyto-oestrogens on postmenopausal cortical bone loss. However, no conclusions can be drawn about effects of higher doses of phyto-oestrogens. Sponsorship: This study was supported by the Dutch Prevention Fund, a charity organisation.
Introduction
Osteoporosis is a major public health problem in elderly populations around the world, in particular in women. Recent estimates suggest that 30% of postmenopausal white women in the United States and 23% of women aged 50 years and over in Europe have osteoporosis (Cooper and Barrett-Connor, 1996) . More than half of these women are estimated to have also sustained a low trauma fracture. Worldwide there were about 1.66 million hip fractures in 1990 and this number is expected to continue to rise in the future (Melton, 1996) .
The risk of developing osteoporosis after the menopause is largely determined by the peak bone mass obtained at young adult age on the one hand, and the rate of bone loss after the menopause on the other. Postmenopausal bone loss is primarily caused by the sharp decrease in oestrogen levels that is inherent to menopause. Hormone replacement therapy (HRT) is effective in the prevention of bone loss in early menopause (Recker, 1993) . Oestrogens are combined with low-dose progestins to prevent oestrogen-induced endometrial cancer. However, there is evidence that the use of oestrogen, with or without progestin, increases the risk of breast cancer (Collaborative Group on Hormonal Factors in Breast Cancer, 1997) . This potential drawback, in combination with the low compliance to HRT observed in some populations (Ravnikar, 1987) , perhaps due to an aversion to the prolonged use of some kinds of medication, stimulates the investigation of the role of dietary compounds in the prevention of postmenopausal bone loss.
In Italy, a number of trials support the preventive effect of ipri¯avone on postmenopausal bone loss Agnusdei et al, 1997; Valente et al, 1994) . Ipri¯avone is a synthetic iso¯avone; iso¯avones are natural plant hormones with an oestrogen-like structure, with soy products as their predominant source. The main representatives of this class of compounds are genistein and daidzein. Iso¯avones have been postulated to play a role in the prevention of a number of chronic diet-related diseases (Adlercreutz & Mazur, 1997) . It is also hypothesised that dietary intake of iso¯avones has a bone-sparing effect on postmenopausal bone loss. Limited evidence from animal experiments (Anderson et al, 1995 (Anderson et al, , 1996 ; Blair, 1996; Fanti et al, 1996) seems to support this hypothesis. Intervention studies with iso¯avones are under way, but so far results from human studies have not been reported.
We investigated the relation between long-term excretion of iso¯avones, as a marker of dietary intake, and the rate of cortical bone loss at the radius in a 10-year followup study among perimenopausal women in the Netherlands. From 1979 From to 1989 healthy early postmenopausal women participated in a prospective study of cortical bone loss in relation to habitual calcium intake. None of them had a history of diabetes mellitus, renal or bone disease, or had undergone major gynaecological surgery or taken any medication known to affect calcium or bone metabolism (such as oestrogens, thiazide diuretics, corticosteroids, vitamin D in pharmacological dosages or calcium supplements of more than 500 mg/day). Participants were recruited in 1978, by inviting all women born between 1922 and 1931 and living in the community of Ede, The Netherlands. After the ®rst examination, 264 eligible healthy women consented to participate and were enrolled in the study. At the end of the follow-up period the data of 43 participants could not be evaluated because they had dropped out for various reasons (such as moving to another city). Of the remaining 221 women, 67 were put on medication known to in¯uence calcium and bone metabolism, leaving the data of 154 women to be evaluated (Beresteijn et al, 1990) . All participants used their habitual diet during the study period and care was taken to avoid in¯uencing them in this respect.
Methods

Population
Of the population of 154 women, 32 women had a rate of cortical bone loss at the radius of 0.5% per year or less over the ®rst 5 years of the study; 35 women had an annual rate of cortical bone loss of 2.5% or more. Seven years after the end of the 10-year follow-up, average urinary excretion of dietary phyto-oestrogens during the study period was determined in these two groups.
Data collection
During the 10-year follow-up, annual measurements were performed of bone mass of the radius, body weight and height, dietary intake of calcium and other nutrients, and blood and 24-h urine samples were collected. To exclude seasonal variations, all measurements were performed annually for each individual at the same time of the year (between January and June).
Cortical bone mineral content (BMC) of the radius was measured by single-photon absorptiometry (125I, NorlandCameron Bone Mineral Analyzer, type 178) and calculated as the mean of ®ve scans of the distal third of the nondominant radius. Results were expressed as g/cm and adjusted for bone width (BMD, g/cm 2 ). The long-term coef®cient of variation of the bone mass measurements was 1.1%. Rates of BMD loss were calculated from individual regression equations of BMD versus time and expressed as percentage of the initial value.
Food consumption was estimated by a trained dietitian using the cross-check dietary history method. Calcium and vegetable protein intake were calculated by means of a computer program based on the Dutch Food Composition ) ).
Biochemical analyses
For each individual in the groups selected on low or high rate of bone loss (n 67), an aggregate sample was made from the annually collected urine samples, proportional to the 24-h volume. Phyto-oestrogens in urine were analysed by gas chromatography ± mass spectrometry (GC-MS) (Morton et al, 1994) . Urine (50 ml) was aliquoted by weight into a silanised B19 test tube and 0.1 M sodium acetate buffer, pH5.0 (2.0 ml) was added. A cocktail of deuterated internal standards, containing deuterated analogues of enterodiol, enterolactone, equol, daidzein and genistein, was added in methanol (50 ml). After equilibration at room temperature for 30 min, b-glucuronidase/aryl sulphatase (Helix pomatia) was added in 0.1 M acetate buffer. The mixture was incubated overnight at 37 C and then extracted with fractionated diethyl ether (5 ml). The organic layer was blown to dryness under nitrogen, dissolved in a mixture of chloroform ± heptane ± methanol (10:10:1; 200 ml) and applied to the top of a short column (361 cm) of Sephadex LH20 constructed in a silanised glass Pasteur pipette. The column was washed with chloroform ± heptane ± methanol (10:10:1; 5 ml) and this wash was discarded. The iso¯avones and lignans present in the sample were eluted with methanol (2 ml), which was blown to dryness under nitrogen at 60 C. The extract was derivatised for GC-MS by reaction with N-(t-butyldimethylsilyl)-N-methyltri¯uoroacetamide containing 1% t-butyldimethylsilyl chloride (100 ml) in acetonitrile (100 ml) at 65 C for 2 h, to form the t-butyldimethylsilyl ethers of the analytes and internal standards. The reaction mixture was blown to dryness under nitrogen gas and dissolved in cyclohexane (50 ml) for analysis. Calibration standards were derivatised in the same manner.
Gas chromatography ± mass spectrometry was carried out using a Fison's Instruments (Manchester, UK) MD800 benchtop quadrupole mass spectrometer coupled to a Fison's Instruments GC8000 chromatograph. The gas chromatograph housed a 15 m60.25 mm DB5MS (0.25 mm phase thickness) capillary column (J & W Scienti®c, CA, USA) and was programmed from 250 C to 280 C at 49.9 C/min under a helium pressure of 50 kPa. The interface was maintained at 275 C and the source at 250 C. Peak height ratios of analyte to internal standard were measured for each sample and calibration standard using MassLab software (Fison's Instruments, Manchester, UK) and concentrations were determined by reference to standard curve. Concentrations were expressed relative to urinary creatinine. Biochemical markers of bone turnover were determined in serum (alkaline phosphatase, osteocalcin, 1,25-dihydroxyvitamin D) and urine (hydroxyproline), as previously described (Beresteijn et al, 1986) .
Statistical analyses
The distributions of the phyto-oestrogen concentrations were very much skewed and could not be normalised by transformation. Therefore, median values and 25th and 75th centiles of the distribution are given and differences between the groups with low and high rate of bone loss were tested with the Kruskall ± Wallis test. For height, weight and BMI, calcium and vegetable protein intake, and biochemical parameters measured in serum or urine, Bone loss in post menopausal women AFM Kardinaal et al the average values over the 10-year follow-up period were calculated; differences between the groups were tested with Student's t-test. The associations between the following variables and phyto-oestrogen excretion (genistein, daidzein, equol and enterolactone, respectively) were evaluated by Pearson correlation analysis: age, years since menopause, height, weight, body mass index, dietary intake of calcium, vegetable protein and dietary ®bre, serum concentrations of alkaline phosphatase, osteocalcin and 1,25-dihydroxyvitamin D, and urinary hydroxyproline/creatinine ratio. The association between phyto-oestrogen excretion and rate of cortical bone loss was estimated by linear regression analysis, with adjustment for age, years since menopause and body mass index. Rate of cortical bone loss over the whole study period (1980 ± 1989) was measured for 63 subjects: two subjects in both groups had incomplete data due to drop-out, hysterectomy or death. All analyses were performed with the SAS statistical package.
Results
Women with a low rate of bone loss (LR) had higher body weight and BMI than women with a high rate of bone loss (HR) ( Table 1 ). The HR group was on average slightly longer after menopause (P 0.07). Concentrations of serum osteocalcin and 1,25-hydroxyvitamin D and of urinary hydroxyproline were on average signi®cantly higher in the HR group. The initial cortical bone density at the radius was similar in both groups; there were no differences in usual intake of calcium and vegetable protein.
Excretion of the iso¯avonoids did not differ between the LR and HR group (Table 2) , although median excretion was consistently higher in the LR group (for daidzein, P 0.09). Equol concentrations were below the detection level in 10 samples (5 from the LR and 5 from the HR group). Enterolactone excretion was signi®cantly higher in the HR group (P`0.05).
Excretion of the individual iso¯avonoids was not associated with any of the covariates measured; total iso¯avone excretion was positively associated with body weight (r 0.26) and body mass index (r 0.25). Enterolactone excretion was inversely correlated with body mass index (r 7 0.24, P 0.05) and positively correlated with intake of vegetable protein (r 0.23, P 0.07) and dietary ®bre (r 0.28, P`0.05). Iso¯avonoids and enterolactone excretion were not associated with radial bone density at the start of the study in 1980, nor with biochemical markers of bone turnover.
The relation between phyto-oestrogen excretion and the rate of cortical bone loss was examined in a multiple linear regression model, with adjustment for age, years since menopause and body mass index (Table 3 ). The equol excretion was a signi®cant determinant of the variation in bone loss over the period 1980/1985, but not for the whole study period 1980/1989. Higher enterolactone excretion was associated with higher rates of bone loss in the period 1980/1989 (P`0.05). Additional adjustment for intake of calcium, vegetable protein or dietary ®bre did not substantially change the results, although the contribution of enterolactone was no longer statistically signi®cant when ®bre intake was included in the regression model.
Discussion
This observational longitudinal study among healthy, early postmenopausal women in the Netherlands evaluated whether the intake of phyto-oestrogens in a habitual, lowphyto-oestrogen diet, assessed by urinary phyto-oestrogen excretion, is related to the rate of cortical bone loss around n 22 and 21, respectively *P 0.05; **P 0.01; ***P 0.001; ****P 0.0001. Bone loss in post menopausal women AFM Kardinaal et al menopause. In contrast with the hypothesis, women with a relatively high rate of bone loss had signi®cantly higher urinary excretion of enterolactone than women with a low rate of bone loss, while equol excretion was also weakly positively associated with rate of cortical bone loss. The difference between the 25th and 75th centiles of equol excretion is associated with 0.26% bone loss per year, in the years immediately after the menopause. For enterolactone this difference is associated with an increase in rate of bone loss of 0.07% per year. Excretion of the main iso¯avones genistein and daidzein was not associated with the rate of cortical bone loss. The women in this study consumed a normal Dutch diet; there were no vegetarians among them. The main food source of iso¯avonoids in the present study is unknown. Iso¯avonoids are present in soy products, but these are consumed by only 6% of Dutch women aged 50 ± 65 years (Anonymous, 1993) . Soy protein is added to many manufactured products and could thus add to the dietary intake in this population. Enterolactone is produced by bacteria in the colon from precursors mainly in grains, legumes, oilseeds and vegetables (Thompson et al, 1991) , which form a more substantial part of the diet.
The low intake of iso¯avonoid sources is re¯ected in the low level of urinary excretion of iso¯avonoids in our population. Urinary excretion of iso¯avonoids is dose dependent at low to moderate levels of soy-protein consumption (Karr et al, 1997) . Equol is a metabolite of daidzein, but is excreted by some individuals and not by others (Setchell et al, 1984) ; this ®nding is reproduced in our study, where equol excretion was below the detection level in 10 subjects. Since phyto-oestrogen excretion depends on recent dietary intake and there may be other sources of within-subject variation, in this study a pooled sample was prepared from yearly samples collected over a 10-year period, as a better indicator of usual intake than a single measure. Phyto-oestrogen excretion was expressed per gram creatinine and not per 24 h, to take into account possible incomplete urine collection by some subjects and evaporation of part of the samples during storage. The urine samples in which the phyto-oestrogens were determined had been stored at 7 20 C for 6 ± 16 years. There is little information about the stability of these compounds over such a period. However, it is unlikely that any deterioration of phyto-oestrogens would differ between the groups with either low or high rates of bone loss. Loss during storage could therefore not explain our ®ndings of a difference in equol and enterolactone levels.
Phyto-oestrogens are an example of bioactive components in food that have been suggested to play a role in the prevention of a range of chronic, diet-related diseases (Adlercreutz & Mazur, 1997; Murkies et al, 1998) . Most of the epidemiological and experimental research so far has focused on the potential role of iso¯avonoids and lignans in cancer protection via different mechanisms (Adlercreutz, 1995) . More recently, evidence from animal studies suggests that positive effects of phytoestrogens might be expected on cardiovascular risk factors (Anthony et al, 1996) and short-term interventions in postmenopausal women indicate possible bene®cial effects on menopausal symptoms such as hot¯ushes (Brzezinski et al, 1997; Albertazzi et al, 1998) . The potential preventive effects of phyto-oestrogens are supported by cross-cultural comparisons between Asian and Western populations, with respect to risk of speci®c types of cancer and menopausal symptoms. The lower incidences of breast, prostate and colon cancer, and the low prevalence of menopausal symptoms in Asian populations coincide with a much higher intake of phyto-oestrogens, mainly iso¯avones from soy. Although such associations do not form evidence for a causal relationship, it is not unlikely that potential bene®cial effects can be expected only at levels of intake that are higher than habitual intakes from Western diets. Recent estimates indicate intakes of 20 ± 50 mg iso¯avones per day in Japan and China (Coward et al, 1993; Fukutake et al, 1996) , while the intake in Western countries is assumed to be less than 1 mg/day. However, a recent case-control study of phyto-oestrogens and breast cancer (Ingram et al, 1997) detected a signi®cant inverse association in a population of Australian women, where phytooestrogen intake is likely to be relatively low in comparison with Asian women, and where the difference in phytooestrogen excretion in the lowest and highest quartiles of excretion was only about a factor 3.
Phyto-oestrogens, in particular the iso¯avones present in soybeans, have also been suggested to have a bene®cial effect on bone preservation, although the mechanism has not yet been cleared up. The evidence from experimental or observational studies is very limited so far. More evidence is available for ipri¯avone, a synthetic iso¯avone, which has been shown to inhibit postmenopausal bone loss in a number of clinical trials. When metabolized, ipri¯avone partly breaks down to daidzein, which can be detected in the urine after supplementation with ipri¯avone. The usual dose in these studies was 600 mg per day, often given in three daily doses of 200 mg. In placebo-controlled studies with a duration of 1 or 2 years, this dose has been shown to inhibit the loss of bone mineral density of the spine (Valente et al, 1994; Agnusdei et al, 1997; de Aloysio et al, 1997; Gambacciani et al, 1997; Gennari et al, 1997) and radius Gennari et al, 1997) that was observed in the control groups. Several studies (Agnusdei et al, 1995; de Aloysio et al, 1997; Gambacciani et al, 1997) have also evaluated the effect of ipri¯avone in combination with low-dose conjugated oestrogens. Low doses of oral conjugated oestrogens (0.3 mg/day) can counteract neurovegetative menopausal symptoms, but higher doses (0.625 mg/day) are required to prevent bone loss in postmenopausal women. The combination of 600 mg ipri¯avone and 0.3 mg oral conjugated oestrogens (Agnusdei et al, 1995) or 25 mg 17-b-oestradiol transdermally per day (de Aloysio et al, 1997) has been shown effective in the prevention of bone loss, observed at low doses of oestrogen. Such a combined therapy is suggested as an approach to prevent or treat all symptoms related to menopause. A recent report showed that the bone-sparing effect of 600 mg ipri¯avone could also be obtained with the combined administration of 400 mg/day of ipri¯avone and 0.3 mg/day of conjugated oestrogens.
There are two reports of a relation between soy protein and bone density. Bone loss in ovariectomized rats was prevented by a soy-protein diet, in comparison with a casein diet (Arjmandi et al, 1996) . Erdman et al, (1996) have reported a signi®cant increase in bone mineral content and bone mineral density of the lumbar spine in postmenopausal women receiving a daily dose of 40 g soy protein containing 2.25 mg iso¯avones/g protein for 6 months, in comparison with a control group receiving protein from casein/nonfat dry milk. Preliminary reports (Anderson et al, 1996; Blair, Bone loss in post menopausal women AFM Kardinaal et al 1996; Fanti et al, 1996) indicate that genistein is able to prevent bone loss in ovariectomized rats. Another preliminary report (Anderson et al, 1995) compares the effect of genistein on the retention of cancellous bone tissue in rats, in contrast to Premarin, an oestrogen with established boneretaining properties, and control diets. Genistein was given in three doses (1.0, 3.2 and 10.0 mg/d). Genistein at the lowest dose had a similar effect to Premarin in maintaining trabecular bone tissue, but at higher doses it had essentially no retentive effect on bone tissue.
Although a preventive effect of phyto-oestrogens on bone loss is biologically plausible, given their structural similarity to oestradiol, there are as yet no results from human studies to support this. Our study ®nds no relation between genistein or daidzein excretion and the rate of cortical bone loss. This lack of association may be explained by the low levels of intake, probably too low to compensate in any way the drastic decrease in natural oestrogens after the menopause. For equol and enterolactone we unexpectedly found that higher excretion is associated with higher rate of bone loss. This is an indication that the group with high bone loss consumes larger quantities of grains and legumes (including soy protein), which is supported by the positive correlation between enterolactone excretion and intake of dietary ®bre. However, the positive association between equol and enterolactone and rate of bone loss remained after adjustment for intake of dietary ®bre. Whether this could be a causal relation can only be speculated upon. However, it is more likely that equol and enterolactone in this population are markers of unmeasured differences in diet and lifestyle that are associated with differences in rate of bone loss, but could not be adjusted for.
In conclusion, our results suggest that unsupplemented dietary intake of phyto-oestrogens has no preventive effect on early postmenopausal cortical bone loss. No conclusions can be drawn about effects of higher doses of phytooestrogens, either through dietary intervention or use of supplements, or about effects on trabecular bone.
